Patents by Inventor Alastair David Reith

Alastair David Reith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and compounds
    Patent number: 6719520
    Abstract: A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl, or aralkyl; R1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R1 and R3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring; to a human or non-human mammal in need thereof, and compounds of formula I.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: April 13, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Matthew Paul Coghlan, Ashley Edward Fenwick, David Haigh, Julie Caroline Holder, Robert John Ife, Alastair David Reith, David Glynn Smith, Robert William Ward
  • Novel method and compounds
    Publication number: 20040010031
    Abstract: A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): 1
    Type: Application
    Filed: May 28, 2003
    Publication date: January 15, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Matthew Paul Coghlan, Ashley Edward Fenwick, David Haigh, Julie Caroline Holder, Robert John Ife, Alastair David Reith, David Glynn Smith, Robert William Ward
  • KIAA0551 polynucleotides and polypeptides use
    Publication number: 20020019519
    Abstract: The use of KIAA0551 polypeptides and polynucleotides in the design of protocols for the treatment of neuropathies, neuropathic pain, inflammatory and chronic pain, neurodegenerative conditions such as Motor Neuron Disease, Parkinson's Disease, Alzheimer's Disease and other dementias, as well as ischaemic damage in neuronal and cardiac tissues, through disease or infectious agents, among others, and diagnostic assays for such conditions. Also disclosed are methods for producing such polypeptides by recombinant techniques.
    Type: Application
    Filed: June 1, 2001
    Publication date: February 14, 2002
    Inventors: Sharon Bingham, Patrick Case, Sally Neale Lawson, Richard Anthony Newton, Oliver Lars Rausch, Alastair David Reith, Gareth John Sanger
  • KIAA0551 polynucleotides and polypeptides use
    Patent number: 6277979
    Abstract: The use of KIAA0551 polypeptides and polynucleotides in the design of protocols for the treatment of neuropathies, neuropathic pain, inflammatory and chronic pain, neurodegenerative conditions such as Motor Neuron Disease, Parkinson's Disease, Alzheimer's Disease and other dementias, as well as ischaemic damage in neuronal and cardiac tissues, through disease or infectious agents, among others, and diagnostic assays for such conditions. Also disclosed are methods for producing such polypeptides by recombinant techniques.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: August 21, 2001
    Assignee: SmithKline Beecham plc
    Inventors: Sharon Bingham, Patrick Case, Sally Neale Lawson, Richard Anthony Newton, Oliver Lars Rausch, Alastair David Reith, Gareth John Sanger